295 Results
Sort By:
Published on October 23, 2020
To protect our bodies from cancers such as melanoma, the immune system uses a monitoring system called immune surveillance that detects and destroys premalignant or malignant cells in the body. However, the immune system can have an alter ego at times, favoring tumor development instead of destroying the premalignant or…
Published on May 26, 2020
Patients with the skin cancer melanoma who have inherited a specific variant of the cholesterol carrying gene APOE, which is associated with increased risk for Alzheimer’s and other diseases, have increased survival compared with people who have inherited other variants of this gene. The research, which was published in the…
Published on February 4, 2020
Levels of circulating tumor cells (CTCs), measured by liquid biopsy, were independently associated with relapse in patients with stage III melanoma, according to a recent study from researchers at the University of Texas MD Anderson Cancer Center. The study was published in Clinical Cancer Research. “Our findings are significant, given that there is…
Published on January 8, 2020
Scientists at Sanford Burnham Prebys Medical Discovery Institute, in collaboration with researchers at NYU Langone’s Perlmutter Cancer Center have identified a new potential strategy for boosting the immune system’s ability to fight cancer. Studies in gene knockout mice suggested that a protein known as Siah2 is involved in the control of…
Published on October 9, 2019
Investigators at the Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have just released findings from a new study revealing that differences at the single-cell level can predict responses to initial BRAF inhibitor therapy and that leveraging these differences may improve patient outcomes. Patients with…
Published on September 30, 2019
Scientists headed by a team at the University of California, San Francisco (UCSF), now report on a new approach to diagnosing melanoma that uses microRNA (miRNA) biomarkers to indicate the presence of even just a few melanoma cells in biopsies of skin tumors that may contain predominantly benign cells. “miRNAs…
Published on March 14, 2019
Myriad Genetics said today it has received a final local coverage determination for its myPath Melanoma test from the Medicare Administrative Contractor Palmetto GBA MolDx. myPath Melanoma is designed to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology, according to Myriad. “We…
Published on August 24, 2018
Researchers at the Mount Sinai School of Medicine and The University of Sydney, Australia have discovered a previously unknown mechanism of drug resistance in a subtype of melanoma patients. Led by Emily Bernstein, Ph.D., associate professor of oncological sciences and dermatology at the Icahn School of Medicine at Mount Sinai,…
Published on July 5, 2018
Sponsor: Castle Biosciences Castle Biosciences has launched DecisionDx-CMSeq test that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to cutaneous melanoma (CM). The test will complement the company’s DecisionDx-Melanoma GEP test that predicts individual risk of recurrence in patients with melanoma. DecisionDx-CMSeq evaluates DNA mutations in the…
Published on March 5, 2018
A rare resistance mutation first thought to appear in melanoma following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along, poised to stop the treatment in its tracks before it could begin, according to a recent study. Lawrence Kwong, Ph.D., assistant professor…
Published on February 1, 2018
Prognostic test maker SkylineDx has announced a collaboration with Mayo Clinic to assist in the development of novel diagnostic tests intended to aid clinicians in the selection of therapies and in the care of patients with melanoma. The work will focus on optimizing and developing an algorithm to identify risk…
Published on January 5, 2018
Researchers from Boston University School of Medicine, Johns Hopkins University, Università di Pavia, Harvard Medical School, and the University of Leicester have announced development of a compound that successfully inhibits the growth of melanoma cells by targeting specific epigenetic-modifying proteins. Findings from the new study—published in Nature Communications in an…
Published on December 20, 2017
Scientists at the University of East Anglia (UEA) in Norwich, England recently published research indicating the combination therapy of the immunosuppressive drug lefflunomide when combined with Astra Zeneca's anticancer candidate selumetinib almost completely stopped the growth of a melanoma tumor when given to mouse study models. The findings could bode well…
Published on November 3, 2017
Investigators at The University of Texas MD Anderson Cancer Center and other institutions have just released new data describing how bacteria that reside in the human digestive tract can influence how melanoma responds to immunotherapy, indicating that a probiotic regimen could aid patients receiving an anti-PD-1 immunotherapy for melanoma. Findings…
Published on October 11, 2017
A team of researchers at the Harold C. Simmons Comprehensive Cancer Center in Texas carried out what they claim is the first prospective study looking at the effects of human gut microbiota and metabolites on response to immune checkpoint inhibitor therapy ICT for metastastic melanoma, using either ipilimumab, nivolumab, ipilimumab…